J Cancer 2015; 6(3):203-217. doi:10.7150/jca.10640


Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?

Carolien A.E. Koks1✉, Steven De Vleeschouwer2,3, Norbert Graf4, Stefaan W. Van Gool1,5

1. Pediatric Immunology, Department of Microbiology and Immunology, KU Leuven, Belgium
2. Department of Neurosciences, KU Leuven, Belgium
3. Neurosurgery, University Hospitals Leuven, Belgium
4. Department for Pediatric Oncology, University of Saarland Medical School, Germany
5. Pediatric Neuro-oncology, University Hospitals Leuven, Belgium

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Koks CAE, De Vleeschouwer S, Graf N, Van Gool SW. Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?. J Cancer 2015; 6(3):203-217. doi:10.7150/jca.10640. Available from http://www.jcancer.org/v06p0203.htm

File import instruction


Oncolytic viruses have been seriously considered for glioma therapy over the last 20 years. The oncolytic activity of several oncolytic strains has been demonstrated against human glioma cell lines and in in vivo xenotransplant models. So far, four of these stains have additionally completed the first phase I/II trials in relapsed glioma patients. Though safety and feasibility have been demonstrated, therapeutic efficacy in these initial trials, when described, was only minor. The role of the immune system in oncolytic virotherapy for glioma remained much less studied until recent years. When investigated, the immune system, adept at controlling viral infections, is often hypothesized to be a strong hurdle to successful oncolytic virotherapy. Several preclinical studies have therefore aimed to improve oncolytic virotherapy efficacy by combining it with immune suppression or evasion strategies. More recently however, a new paradigm has developed in the oncolytic virotherapy field stating that oncolytic virus-mediated tumor cell death can be accompanied by elicitation of potent activation of innate and adaptive anti-tumor immunity that greatly improves the efficacy of certain oncolytic strains. Therefore, it seems the three-way interaction between oncolytic virus, tumor and immune system is critical to the outcome of antitumor therapy. In this review we discuss the studies which have investigated how the immune system and oncolytic viruses interact in models of glioma. The novel insights generated here hold important implications for future research and should be incorporated into the design of novel clinical trials.

Keywords: glioblastoma, oncolytic virotherapy, antitumor immunity